Ana Xavier-Magalhães

Ana Xavier-Magalhães

Auto-generated profile, based on publicly available information

Ana Xavier-Magalhães

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
RBRobert J.A. Bell
Robert J.A. Bell
HRH. Tomas Rube
H. Tomas Rube
AXAna Xavier-Magalhães
Ana Xavier-Magalhães
BCBruno Costa
Bruno Costa
AMAndrew Mancini
Andrew Mancini
JCJoseph F. Costello
Joseph F. Costello
Telomerase (TERT) activation is a fundamental step in tumorigenesis. By maintaining telomere length, telomerase relieves a main barrier on cellular lifespan, enabling limitless proliferation driven by oncogenes. The recently discovered, highly recurrent mutations in the promoter of TERT are found in over 50 cancer types, and are the most common mutation in many cancers. Transcriptional activation of TERT, via promoter mutation or other mechanisms, is the rate-limiting step in production of active telomerase. Although TERT is expressed in stem cells, it is naturally silenced upon differentiation. Thus, the presence of TERT promoter mutations may shed light on whether a particular tumor arose from a stem cell or more differentiated cell type. It is becoming clear that TERT mutations occur early during cellular transformation, and activate the TERT promoter by recruiting transcription factors that do not normally regulate TERT gene expression. This review highlights the fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation. These somatic promoter mutations, along with germline variation in the TERT locus also appear to have significant value as biomarkers of patient outcome. Understanding the precise molecular mechanism of TERT activation by promoter mutation and germline variation may inspire novel cancer cell-specific targeted therapies for a large number of cancer patients. Mol Cancer Res; 14(4); 315–23. ©2016 AACR.

20 February 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MPMarta Pojo
Marta Pojo
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
AXAna Xavier-Magalhães
Ana Xavier-Magalhães
AOAna Isabel Oliveira
Ana Isabel Oliveira
TGTiago Gonçalves
Tiago Gonçalves
BCBruno Costa
Bruno Costa
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide

12 January 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AXAna Xavier-Magalhães
Ana Xavier-Magalhães
AOAna I. Oliveira
Ana I. Oliveira
JCJoana Vieira de Castro
Joana Vieira de Castro
MPMarta Pojo
Marta Pojo
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
BCBruno Costa
Bruno Costa

10 January 2020 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
AXAna Xavier‐Magalhães
Ana Xavier‐Magalhães
EMEduarda P. Martins
Eduarda P. Martins
APAfonso A. Pinto
Afonso A. Pinto
MPManuel Melo Pires
Manuel Melo Pires
BCBruno Costa
Bruno Costa
Despite much effort to improve treatments, patients with malignant glioma still present a very poor prognosis that has not changed significantly in the last decades. In this context, it is crucial to better understand glioma pathogenesis to identify new molecular prognostic subgroups and therapeutic targets. WNT6 was recently identified as a new oncogenic molecule in glioblastoma (GBM), with prognostic value in patients, but the mechanisms underlying WNT6 aberrant expression in glioma are still unknown. WNT6 was overexpressed in a subset of gliomas independently of IDH mutations, 1p/19q codeletion status, and WNT6 gene copy number. Interestingly, WNT6 expression is associated with the DNA methylation levels of particular CpG regions at both the WNT6 promoter and the gene body in glioma patient samples. HOXA9, a transcription factor previously associated with poorer clinical outcome in GBM, was identified as a novel transcriptional regulator of WNT6, activating the WNT/β‐catenin pathway in vitro and in vivo. In various cohorts of glioma patients, mRNA levels of WNT6 and HOXA9 were significantly correlated, extending our in vitro and in vivo findings into the clinical setting. Interestingly, this novel molecular link between WNT6 and HOXA9 was not limited to glioma, as they were co‐expressed also in patients with other tumor types. Clinically, WNT6 was a prognostic biomarker of shorter survival in GBM, independently of HOXA9 expression. Concomitant high expression of both WNT6 and HOXA9 identified a subgroup of patients with particularly dismal survival. These findings describe novel WNT6 regulatory mechanisms in GBM, establishing particular DNA methylation patterns and HOXA9 as critical regulators of WNT6 expression in glioma. This HOXA9‐WNT6 molecular link supports WNT signaling in GBM cells and is a powerful prognostic biomarker, highlighting the clinical relevance of this axis in patients. Novel therapies targeting WNT6‐HOXA9 signaling may thus be useful for this deadly disease.

1 September 2015 in Genomics Data
Verified
Journal Article
Open access
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
AXAna Xavier-Magalhães
Ana Xavier-Magalhães
MPMarta Pojo
Marta Pojo
AOAna Isabel Oliveira
Ana Isabel Oliveira
SCSara Correia
Sara Correia
BCBruno Costa
Bruno Costa
The data here described pertain to the article by Pojo et al. (2015) [10] titled “A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide” (Pojoet al., 2015 [10]). HOX genes are part of the homeobox gene family, which encodes transcription factors crucial during embryonic development (Grier et al., 2005; Pearson et al., 2005 [6,9]) and also in post developmental regulation(Neville et al., 2002; Yamamoto et al., 2003; Takahashi et al., 2004;Morgan 2006 [8,14,13,7]). Alterations interfering with the regulation of these genes may lead to tumorigenesis in adults. Due to their contributions in the control of important cellular processes, the deregulation of HOX genes is ultimately correlated with cancer treatment failure and patients' poor prognosis (Golub et al., 1999; Abdel-Fattah et al., 2006 [5,1]; Costa et al.,2010 [4]; Pojo et al., 2015 [10]). Recently, our studies showed that HOXA9 overexpression is associated with poor prognosis in patients with glioblastoma (GBM), the most common and most malignant primary brain tumor. Mechanistically, HOXA9 is associated with resistance to chemotherapy and with pro-proliferative, pro invasive and anti-apoptotic features (Costa et al., 2010 [4]; Pojo et al., 2015 [10]) in GBM in vitro models. Since HOXA9 is a transcription factor, its target genes can be the true biological effectors of its aggressiveness. In this context, whole genome Agilent's microarrays were used to obtain the full transcriptome of HOXA9 in a variety of GBM cell models, including human immortalized astrocytes, established GBM cell lines, and GBM patient derived cell cultures. Here, we provide detailed methods, including experimental design and microarray data analyses,which can be accessed in Gene Expression Omnibus (GEO) under the accession number GSE56517. Additional interpretation of the data is included and supplemented in (Pojo et al., 2015 [10]).

11 April 2013 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
MPMarta Pojo
Marta Pojo
SCSusana R. Cerqueira
Susana R. Cerqueira
TMT. Mota
T. Mota
AXA. Xavier-Magalhães
A. Xavier-Magalhães
SRS. Ribeiro-Samy
S. Ribeiro-Samy
António SalgadoAntónio Salgado
António Salgado